Mots-c vs nad+: what the research actually shows

Last updated 2026-07-24

what is mots-c and what is nad+, actually

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome, specifically in a short open reading frame within the 12S rRNA gene. It's not a vitamin or a cofactor. It's a signaling molecule your cells already make, and under metabolic stress it moves into the nucleus and directly changes which genes get switched on, largely through interaction with nuclear respiratory factors and stress-response elements ^[1][2]. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. Every cell needs it for hundreds of redox reactions and for enzymes like sirtuins and PARPs that manage DNA repair and metabolic signaling. NAD+ levels measurably fall with age in multiple tissues, which is why supplement companies sell NAD+ precursors (NMN, nicotinamide riboside) instead of NAD+ itself, since the intact molecule doesn't cross cell membranes well. So the fair comparison isn't 'peptide vs supplement.' It's a mitochondrial signaling molecule with tissue-specific, receptor-adjacent actions ^[3] versus a universal metabolic cofactor whose depletion is a downstream marker of aging cells generally. They sit in overlapping territory (mitochondrial health, metabolic disease, aging biology) but they don't do the same job.

how do mots-c and nad+ affect mitochondria differently

NAD+ is fuel for the machinery. Without adequate NAD+/NADH cycling, the electron transport chain slows down and sirtuins that regulate mitochondrial biogenesis lose their substrate. Precursor supplementation aims to keep that machinery supplied. MOTS-c works more like a messenger reporting on mitochondrial status. The original 2015 Cell Metabolism paper found that MOTS-c administration in mice prevented diet-induced obesity and age-dependent insulin resistance, and improved insulin sensitivity in mice already obese, effects the authors tied to activation of AMPK and improved glucose handling ^[4]. A 2018 follow-up in the same journal showed MOTS-c translocates to the nucleus under metabolic stress (like glucose deprivation) and regulates nuclear gene expression tied to antioxidant response, distinct from a simple fuel-supply role ^[1]. A 2024 mechanistic paper in iScience found MOTS-c directly binds and activates casein kinase 2 (CK2) in skeletal muscle, linking the peptide to a specific kinase target rather than a general metabolic boost ^[3]. That's a more precise mechanism than most NAD+ precursor studies have pinned down in humans so far.

does mots-c work like nad+ for insulin resistance and metabolic disease

Both have metabolic disease data, but nearly all of it for MOTS-c is preclinical. The foundational MOTS-c paper showed it reduces obesity and insulin resistance in mice ^[4]. A 2022 study in Pharmacological Research found MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model ^[5]. A 2023 review in Metabolites summarized MOTS-c's role in preventing metabolic disorders across several rodent models ^[6], and a 2023 Diabetes & Metabolism Journal review connected MOTS-c mechanistically to diabetes and aging-related disease pathways ^[7]. More recent work has pushed further into diabetic organ damage: a 2025 paper in Cardiovascular Drugs and Therapy reviewed MOTS-c's potential in diabetic cardiomyopathy ^[8], and a 2025 Scientific Reports study found MOTS-c mimicked exercise-associated signaling to reduce diabetic liver fibrosis in a mouse model, acting through the Keap1-Nrf2-Smad2/3 pathway ^[9]. A 2025 paper in Experimental & Molecular Medicine reported MOTS-c prevented pancreatic islet cell senescence in a mouse model of diabetes ^[10]. All of that is animal or cell-culture biology. None of it is a randomized human trial showing MOTS-c lowers HbA1c or improves insulin sensitivity in people. NAD+ precursor research has more human trials in circulation (mostly small, short-duration studies on NMN or NR affecting blood NAD+ levels or minor metabolic markers), but that body of work also hasn't produced FDA-recognized treatment claims. Neither compound is an approved drug for insulin resistance; check Drugs@FDA if you want to verify what has actually cleared approval, which for both is nothing in this space.

is mots-c really an 'exercise mimetic' and is that a fair comparison to nad+

The 'exercise in a pill' label gets attached to MOTS-c constantly, and it's worth being precise about where that comes from. MOTS-c circulating levels rise with exercise, and a 2022 review in Diabetes & Metabolism Journal specifically frames MOTS-c within a mitohormesis model, meaning mild mitochondrial stress from exercise triggers protective signaling, of which MOTS-c appears to be one messenger ^[11]. A broader 2021 review in Biochimica et Biophysica Acta looked at mitochondrial-derived peptides and exercise generally, describing correlational and mechanistic links, not a substitute-for-exercise finding ^[12]. The 2025 Scientific Reports liver fibrosis study literally used the phrase 'mimics exercise' in its title, describing how administered MOTS-c activated pathways similar to those triggered by exercise, in a diabetic mouse model ^[9]. That is a specific finding in a specific disease model, not evidence that injecting MOTS-c gives you the cardiovascular, muscular, and cognitive benefits of actually training. NAD+ marketing carries a similar but slightly different flavor: 'restore your youthful energy' framing based on the fact that NAD+ falls with age. Both categories oversell a real, narrow finding into a lifestyle-replacement claim. If you want the muscular and metabolic adaptations of exercise, the only thing with an actual outcomes literature backing it is exercise. For a closer read on the peptide's known and unknown mechanisms, see the main mots-c overview.

what does mots-c do for muscle that nad+ doesn't (or does)

This is where the two diverge sharply. MOTS-c has a growing muscle-specific literature that NAD+ precursor research doesn't really match in mechanistic detail. A 2022 study in Peptides found MOTS-c promotes muscle differentiation in vitro ^[13]. A 2021 paper in American Journal of Physiology-Endocrinology and Metabolism reported MOTS-c reduces myostatin expression and atrophy signaling in muscle models ^[14], myostatin being a protein that limits muscle growth. A 2024 study in the same journal found MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration in a mouse hindlimb unloading model ^[15]. And the 2024 iScience paper already mentioned showed MOTS-c directly binds and activates CK2 to modulate skeletal muscle function ^[3], giving a specific enzymatic target for that atrophy protection. NAD+'s muscle connection runs through sirtuin activation and mitochondrial biogenesis generally, a broader and less muscle-specific mechanism. If your interest is sarcopenia or disuse atrophy specifically, the MOTS-c animal literature is more targeted. None of this is human dosing data though; anyone quoting a specific atrophy-prevention percentage in people is not citing a real study. For dosing frameworks based on the animal literature, see mots-c dosage and the mots-c 10mg dosage calculator.

mots-c vs nad+ side-by-side comparison

The practical takeaway: these aren't competing products solving the same problem. They're different biological levers being sold into the same longing (mitochondrial vigor, metabolic resilience, feeling less old).

is mots-c fda-approved, and how does that compare to nad+ supplements

No. MOTS-c is not an FDA-approved drug. You can check Drugs@FDA yourself; it won't come up. Peptides like MOTS-c fall under a different regulatory question: whether they're legally compoundable. Under 21 U.S.C. 353a, pharmacies can compound drugs for individual patients using bulk substances, but only if those substances meet criteria set by FDA and appear on relevant lists . The FDA maintains a 503A bulks list (21 CFR 216.23) ^[17] and a 503B bulks list (21 CFR 216.24) ^[18] for outsourcing facilities. Whether MOTS-c is currently included, excluded, or under review changes over time; check FDA's nominated substances list directly FDA nominated bulk substances and the 503A bulk drug substances page rather than trusting a vendor's claim about legality. NAD+ precursors (NMN, NR) sit in a different lane almost entirely: they're sold as dietary supplements, which means a lighter regulatory bar (no premarket approval required, but also no permission to make disease-treatment claims under 21 CFR 201.128's definition of intended use) . That's a meaningfully different legal risk profile than an injectable peptide being compounded off a bulks list. If a MOTS-c seller isn't naming a pharmacy or explaining the compounding basis, that's a red flag worth pausing on. See mots-c peptide buy for what a provider-reviewed sourcing path looks like.

what does the safety data show for mots-c compared to nad+

Neither has a large human safety database, but the shape of the concern differs. A 2026 Sports Medicine paper reviewing peptide therapies used for musculoskeletal injuries and athletic performance (including unapproved peptides sold in this space) found that safety and efficacy data for many of these compounds remain limited and inconsistent across the literature ^[19]. That paper is a useful reality check for anyone assuming 'peptide' automatically means 'gentle and natural.' MOTS-c's cell and tissue studies raise a genuinely interesting complication: mitochondrial-derived peptides as a class don't uniformly act as protective agents. A 2018 paper in Rejuvenation Research titled bluntly 'Mitochondrial-Derived Peptides Exacerbate Senescence' found evidence that some of these peptides can worsen, not improve, senescence markers in certain contexts ^[20]. That doesn't mean MOTS-c itself causes senescence broadly; it means the peptide family's effects are context-dependent, and 'more mitochondrial peptide is better' isn't a safe assumption. NAD+ precursors have a longer track record of casual human use (NMN and NR have been sold as supplements for years), with fewer alarming signals reported, but also fewer rigorous long-term studies powered to detect rare harms. Absence of red flags isn't the same as proof of safety at scale. For MOTS-c specifically, injection site reactions and unknowns around long-term dosing are the honest current picture; see mots-c side effects for a fuller rundown.

does mots-c or nad+ have better evidence for anti-aging claims

Neither has strong human anti-aging trial evidence. Full stop. What MOTS-c has is a wide, genuinely interesting preclinical footprint: a 2023 Frontiers in Endocrinology review calls it 'a promising mitochondrial-derived peptide for therapeutic exploitation,' summarizing findings across metabolic, cardiovascular, and stress-response domains ^[16]. A 2019 BioEssays review frames MOTS-c specifically as a mitochondrial-encoded regulator that talks to the nucleus, a genuinely novel piece of cell biology ^[2]. But breadth of preclinical interest is not the same as depth of human proof. The MOTS-c literature spans bone metabolism ^[21], osteoarthritis cartilage protection via Nrf2 signaling ^[22], antiviral activity against hepatitis B in liver cell and mouse models ^[23], membrane repair mechanisms ^[24][25], lung injury and pulmonary fibrosis models ^[26][27][28], asthma-related airway protection ^[29], and even an ovarian cancer progression study finding MOTS-c suppressed tumor growth by affecting a specific ubiquitination pathway (USP7-mediated LARS1 deubiquitination) ^[30]. That range is either evidence of a genuinely central mitochondrial signaling molecule, or evidence that when a peptide gets popular in research circles, everyone tests it in their disease model of interest. Probably some of both. NAD+'s anti-aging story rests more on a single well-established fact (NAD+ declines with age across tissues) extended into a much larger promise than the current human trial data supports. Both fields would benefit from someone running a serious randomized human trial instead of another mouse study.

can you combine mots-c and nad+, and does it make sense to

There's no published human trial testing MOTS-c and NAD+ precursors together, so any claim about a combined benefit is speculation, not data. Mechanistically, it's not an absurd idea. NAD+ supports the broad cellular energy state that MOTS-c signaling depends on, since MOTS-c's stress-sensing role (per the 2018 Cell Metabolism nuclear translocation paper) ^[1] happens in cells that need functioning mitochondrial and nuclear crosstalk in the first place. But 'not absurd mechanistically' and 'proven to work together' are very different claims, and right now nobody has run the combination study. If you're already using an NAD+ precursor and considering adding MOTS-c, that's a decision to make with a provider who understands both the compounding legality question and your actual health picture, not a stacking protocol lifted from a forum post. MOTS-c Co's editorial position: treat MOTS-c as an interesting research compound with real mechanistic depth and essentially no human efficacy trials, and treat any vendor claiming proven anti-aging or exercise-replacement benefits with real skepticism. If you're going to try it, do it through a provider-reviewed path with a named compounding pharmacy behind it, not an anonymous online seller.

how should you actually decide between mots-c and nad+

If your actual goal is measurable metabolic or muscle-specific outcomes and you're comfortable with unapproved-peptide territory and its regulatory gray zones, MOTS-c has more mechanistic specificity in the animal literature, particularly around muscle atrophy ^[15][14] and insulin resistance ^[4][5]. If your goal is a lower-friction, well-established supplement category with a simpler legal picture, NAD+ precursors (NMN, NR) are the more conventional choice, sold over the counter as supplements rather than compounded peptides. Neither is a proven longevity intervention in humans. Anyone telling you otherwise is ahead of the data. What's real: MOTS-c is genuinely interesting biology, with a mitochondrial-to-nucleus signaling mechanism ^[1][2] and a fast-growing list of disease models where it shows effects ^[16]. What's not real yet: a human trial showing it treats diabetes, prevents sarcopenia, or extends lifespan in people. If you want the practical mechanics, next stop is mots-c peptide injection for how it's actually administered in the protocols people are running, alongside mots-c dosage for typical ranges drawn from the available literature.

Frequently asked questions

Is mots-c the same thing as nad+?

No. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that acts as a signaling molecule, moving into the nucleus under metabolic stress to regulate gene expression ^[6]. NAD+ is a coenzyme required for hundreds of cellular reactions. They're both tied to mitochondrial health but are structurally and functionally unrelated molecules.

Which has better human clinical trial data, mots-c or nad+?

Neither has strong human trial data for the claims marketed around it. MOTS-c's evidence base is almost entirely rodent and cell-culture studies ^[2][4][7]. NAD+ precursors have more small human pharmacokinetic studies in circulation, but no trial has established anti-aging or disease-reversal outcomes in people for either compound.

Is mots-c legal to buy in the US?

It depends on whether MOTS-c currently appears on FDA's 503A or 503B bulk drug substances lists, which change over time. Check the FDA's bulk drug substances page directly ^[31][32] rather than trusting a seller's claim. It is not an FDA-approved drug regardless of compounding status.

Does mots-c really work like exercise in a pill?

Not exactly. MOTS-c levels rise with exercise, and a 2025 study found administered MOTS-c activated exercise-associated liver signaling pathways in diabetic mice ^[30], but that's a specific finding in a disease model, not proof it replicates the full range of exercise benefits in humans.

Can nad+ supplements reverse mitochondrial aging?

NAD+ levels do decline with age, and NAD+ is required for mitochondrial function and sirtuin activity. But no human trial has shown NMN or NR supplementation reverses mitochondrial aging or produces the broad rejuvenation effects often implied in marketing. The decline-with-age fact is real; the reversal claim is not established.

Does mots-c help with insulin resistance more than nad+?

MOTS-c reduced obesity and insulin resistance in the original 2015 mouse study ^[2] and relieved hyperglycemia in a gestational diabetes rodent model ^[4]. NAD+ precursor research on insulin resistance is comparatively thinner in mechanistic specificity. Both bodies of evidence are preclinical or small-scale; neither supports a human treatment claim yet.

What are the side effects of mots-c compared to nad+ supplements?

A 2026 review of peptide therapies for performance and injury use found safety and efficacy data for many unapproved peptides, including this class, remain limited and inconsistent ^[11]. NAD+ precursors have a longer track record of casual use with fewer reported concerns, but neither has strong long-term human safety data.

Does mots-c help build muscle?

In cell and animal studies, yes: MOTS-c promoted muscle differentiation in vitro ^[12], reduced myostatin and atrophy signaling ^[25], and protected against immobilization-induced muscle atrophy in mice ^[13]. There's no human trial confirming muscle-building effects in people at this point.

Is mots-c fda approved for any condition?

No. MOTS-c has no FDA-approved indication. You can verify this directly using the Drugs@FDA database. Its regulatory status is instead governed by compounding rules under 21 U.S.C. 353a and whether it appears on the FDA's bulk drug substances lists ^[31][32][33].

Can you take mots-c and nad+ together?

No published human study has tested the combination, so any claimed benefit from combining them is speculation rather than data. Mechanistically it's plausible they'd complement each other, since MOTS-c's stress-response signaling depends on cellular energy status, but that hasn't been tested directly.

Why do people call mots-c the 'exercise mimetic peptide'?

Because circulating MOTS-c rises with exercise and is discussed within a mitohormesis framework, where mild mitochondrial stress from exercise triggers protective signaling ^[28]. That's a real correlation and mechanistic hypothesis, not proof that MOTS-c injections replicate exercise's cardiovascular, muscular, and cognitive benefits.

Where does mots-c come from in the body?

MOTS-c is encoded by a short open reading frame within the mitochondrial 12S rRNA gene, making it one of a small class of mitochondrial-derived peptides. It's produced naturally; supplementation involves administering a synthetic version of this endogenous peptide.

Sources

1. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation across metabolic, cardiovascular, and stress-response domains
2. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c administration reduced obesity and age-dependent insulin resistance and improved insulin sensitivity in mice
3. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination in a study model
4. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model
5. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus under metabolic stress to regulate nuclear gene expression
6. PubMed, Metabolites 2023 (PMID 36677050): Review summarizing MOTS-c's role in preventing metabolic disorders across rodent models
7. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): Review of MOTS-c's potential relevance to diabetic cardiomyopathy
8. PubMed, iScience 2024 (PMID 39559755): MOTS-c directly binds and activates CK2 to modulate skeletal muscle function
9. PubMed, BioEssays 2019 (PMID 31378979): MOTS-c is characterized as a mitochondrial-encoded regulator of the nucleus
10. PubMed, Sports Medicine 2026 (PMID 41966639): Review found safety and efficacy data for unapproved peptide therapies used in athletic performance and injury remain limited and inconsistent
11. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
12. PubMed, American Journal of Physiology-Endocrinology and Metabolism 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration in a mouse model
13. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in regulating bone metabolism
14. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism
15. PubMed, Gut 2024 (PMID 37788894): MOTS-c shows a mitochondrial remodeling function contributing to antiviral activity during hepatitis B infection
16. PubMed, Theranostics 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation to the membrane
17. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling
18. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c identified as a potential anti-pulmonary fibrosis factor derived by mitochondria
19. PubMed, International Immunopharmacology 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in allergic asthma by inhibiting epithelial apoptosis via the Nrf2 pathway
20. PubMed, Diabetes & Metabolism Journal 2023 (PMID 36824008): Review connecting MOTS-c mechanistically to diabetes and aging-related disease pathways
21. PubMed, Autophagy 2026 (PMID 42153537): MOTS-c ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation in a study model
22. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in a study model
23. PubMed, American Journal of Respiratory Cell and Molecular Biology 2025 (PMID 40035775): MOTS-c promotes glycolysis via the AMPK-HIF-1α-PFKFB3 pathway to ameliorate cardiopulmonary bypass-induced lung injury
24. PubMed, American Journal of Physiology-Endocrinology and Metabolism 2021 (PMID 33554779): MOTS-c reduces myostatin expression and muscle atrophy signaling
25. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of mitochondrial-derived peptides and their relationship to exercise
26. PubMed, Rejuvenation Research 2018 (PMID 30058454): Study found some mitochondrial-derived peptides can exacerbate senescence markers in certain contexts
27. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Review frames MOTS-c within a mitohormesis model linking exercise-induced mitochondrial stress to protective signaling
28. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimicked exercise-associated signaling to reduce diabetic liver fibrosis via Keap1-Nrf2-Smad2/3 pathway in a mouse model
29. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the final bulk drug substances list eligible for 503A pharmacy compounding
30. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances list eligible for 503B outsourcing facility compounding
31. Cornell Law, 21 U.S.C. 353a: Establishes the legal conditions under which pharmacies may compound drugs from bulk substances
32. eCFR, 21 CFR 201.128: Defines 'intended use' governing what disease claims a supplement or unapproved product may legally make